[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620597":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":36,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":59,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients undergoing endomyocardial biopsy following clinical indication",null,"All patients with a clinical indication for EMB without regard to certain disease types. Typically these patients are after heart transplantation, amyloidosi or with a cardiomyopathy, including dilated-, hypertrophic- or inflammatory cardiomyopathy.",[13],{"name":14,"affiliation":15,"role":16},"Lars Michel, PD Dr. med.","Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen, Germany","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+49 0201 723 84841","lars.michel@uk-essen.de",[23],{"facility":15,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"RECRUITING","Essen","North Rhine-Westphalia","45147","Germany","DE",{"type":31,"coordinates":32},"Point",[33,34],7.01228,51.45657,{"lat":34,"lon":33},{"type":16,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Lars Michel","Head of Cardiomyopathies and Heart Failure","100620597",false,"NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.","ALL","18 Years",{"count":47,"type":48},216,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[52,53,54,55,56,57,58],"Heart Transplantation","Dilated Cardiomyopathy (DCM)","Hypertrophic Cardiomyopathy (HCM)","Myocarditis, Pericarditis","Amyloidosis Cardiac","Cardiomyopathies","Sarcoidosis of the Heart",[60,61],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":64,"type":65},"2026-01-22","ACTUAL",{"date":67,"type":65},"2025-10-27",{"date":69,"type":48},"2028-09-30",{"name":5,"class":6},1]